Circulating Osteoprotegerin and sRANKL Concentrations in the Perinatal Period at Term

Briana, Despina D.; Boutsikou, Maria; Baka, Stavroula; Hassiakos, Dimitrios; Gourgiotis, D; Malamitsi‐Puchner, Ariadne

doi:10.1159/000211666

Cited by 21 publications

(11 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement to our data, Naylor et al obtained low OPG levels in neonates and suggested its placental origin (23), a concept supported by the marked decrease of OPG in maternal blood after delivery. Likewise, low OPG in neonatal serum was observed by Brianna et al and the authors concluded that it could represent high bone resorption rates (40). Indeed, in our study, an inverse correlation was noticed between umbilical serum OPG and umbilical serum BAP, a marker of bone turnover.…”

Section: Discussionsupporting

confidence: 79%

Relationships of Umbilical and Maternal Adiponectin, Resistin and Osteoprotegerin to Maternaland Newborn Anthropometric Characteristics

Georgescu¹

2011

Acta Endo (Buc)

View full text Add to dashboard Cite

Introduction. Adiponectin, resistin and osteoprotegerin (OPG) are cytokines expressed in the adipose tissue. Pregnancy is associated with gradually increased maternal levels of these molecules, also detected in significant amounts in umbilical cord blood serum samples.Aim, patients and methods. To establish the relationships of maternal and umbilical adiponectin, resistin and OPG levels to both maternal and fetal anthropometric measurements and insulin sensitivity, 28 mother-newborn pairs were enrolled in the study. Blood samples were collected in a fasting state, after delivery, and serum insulin, C-peptide, sex hormone-binding globulin, adipocytokines, OPG and bone specific alkaline phosphatase (BAP) were measured.Results. Compared to maternal values, umbilical serum adiponectin levels were about 3-fold higher; additionally, significantly higher resistin and lower OPG levels were observed. Stratification of umbilical and maternal adiponectin levels according to tertiles of birth body weight demonstrated significantly lower maternal adiponectin levels by tertiles of neonatal body weight. No relationships were noticed between infant birth weight and maternal or umbilical serum resistin and OPG, respectively. Umbilical resistin was significantly associated to both maternal resistin and umbilical adiponectin. Multiple regression analysis showed that maternal BMI, umbilical insulin, C-peptide and resistin explained 71.83% of umbilical serum adiponectin variability. Umbilical resistin was independently predicted by umbilical adiponectin, umbilical C-peptide and maternal BMI, and the model explained 81.49% of umbilical resistin levels.Conclusions. In human, umbilical serum adiponectin and resistin levels are significantly higher compared to adults. These adipokines may mediate the effects of maternal body mass on fetal development. The biology of the OPG/RANKL cytokine system in fetuses and newborns needs further research.

show abstract

Section: Discussionsupporting

confidence: 79%

Relationships of Umbilical and Maternal Adiponectin, Resistin and Osteoprotegerin to Maternaland Newborn Anthropometric Characteristics

Georgescu¹

2011

Acta Endo (Buc)

View full text Add to dashboard Cite

show abstract

“…Neither the observed relationships nor infant characteristics were significantly influenced by maternal or infant race. A study by Briana et al found no significant association between cord OPG concentrations and birth weight, and no difference in OPG between appropriate-for-gestational-age (n 5 20) and intrauterine growth restriction (n 5 20) infants; 23 however, their relatively small sample size may have limited their ability to detect associations. Our observed association between cord OPG concentrations and neonatal birth weight z-score may hint at a role for OPG in neonatal accrual of body stores of fat, bone or muscle.…”

Section: Discussionmentioning

confidence: 95%

Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight z-score

Essley

McNanley

Cooper

et al. 2011

J Dev Orig Health Dis

View full text Add to dashboard Cite

Osteoprotegerin (OPG) is involved in the regulation of bone turnover, but little is known about this protein during pregnancy or among neonates. We undertook a prospective longitudinal study to identify relationships between OPG, markers of bone turnover and birth outcomes in 155 pregnant adolescents (13–18 years) and their newborns. Maternal blood samples were collected at mid-gestation and at delivery. Cord blood was obtained at delivery. Serum OPG, estradiol and markers of bone formation (osteocalcin) and resorption (N-telopeptide) were assessed in all samples. Placental OPG expression was assessed in placental tissue obtained at delivery. Bone markers and OPG increased significantly from mid-gestation (26.0 ± 3.4 weeks) to delivery (39.3 ± 2.6 weeks). Neonatal OPG was significantly lower, but bone turnover markers were significantly higher than maternal values at mid-gestation and at parturition (P < 0.001). African-American adolescents had higher concentrations of OPG than Caucasian adolescents at mid-gestation (P = 0.01) and delivery (P = 0.04). Gestational age and estradiol were also predictors of maternal OPG at mid-gestation and delivery. OPG concentrations in cord blood were correlated with maternal OPG concentrations and were negatively associated with infant birth weight z-score (P = 0.02) and ponderal index (P = 0.02). In conclusion, maternal OPG concentrations increased across gestation and were significantly higher than neonatal OPG concentrations. Maternal and neonatal OPG concentrations were not associated with markers of bone turnover or placental OPG expression, but neonatal OPG was inversely associated with neonatal anthropometric measures. Additional research is needed to identify roles of OPG during pregnancy.

show abstract

“…The rapid post partum fall in OPG suggests a placental origin, which has been corroborated by the finding of a high concentration of OPG in placental membranes (40). The circulating levels of RANKL have been investigated in studies that have reported parallel changes to those of OPG (41,42). However, these data require a cautious interpretation because of the methodological problems with current assays for measurement of serum RANKL.…”

Section: Other Regulatorsmentioning

confidence: 96%

ENDOCRINOLOGY IN PREGNANCY: Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture

Sanz-Salvador

Garcı́a-Pérez

Tarı́n

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Changes in bone density and bone markers suggest that pregnancy is associated with deterioration of bone mass in the mother. The metabolism of calcium resets to allow for the needs imposed by the building of the fetal skeleton. The fetus contributes to the process through the output of regulators from the placenta. Understanding of the whole process is limited, but some changes are unambiguous. There is an increase in the circulating levels of vitamin D, but its functional impact is unclear. Fetal parathyroid hormone (PTH) and PTH-related peptide (PTHrp) play an indirect role through support of a calcium gradient that creates hypercalcemia in the fetus. Placental GH, which increases up to the end of pregnancy, may exert some anabolic effects, either directly or through the regulation of the IGF1 production. Other key regulators of bone metabolism, such as estrogens or prolactin, are elevated during pregnancy, but their role is uncertain. An increase in the ratio of receptor activator of nuclear factor kappa B ligand (RANKL) to osteoprotegerin (OPG) acts as an additional pro-resorbing factor in bone. The increase in bone resorption may lead to osteoporosis and fragility fracture, which have been diagnosed, although rarely. However, the condition is transitory as long-term studies do not link the number of pregnancies with osteoporosis. Prevention is limited by the lack of identifiable risk factors. When fractures are diagnosed, rest, analgesics, or, when indicated, orthopedic intervention have demonstrated efficacy. Systemic treatment with anti-osteoporotic drugs is effective, but the potential harm to the fetus imposes caution in their use.

show abstract

Circulating Osteoprotegerin and sRANKL Concentrations in the Perinatal Period at Term

Cited by 21 publications

References 61 publications

Relationships of Umbilical and Maternal Adiponectin, Resistin and Osteoprotegerin to Maternaland Newborn Anthropometric Characteristics

Relationships of Umbilical and Maternal Adiponectin, Resistin and Osteoprotegerin to Maternaland Newborn Anthropometric Characteristics

Osteoprotegerin in pregnant adolescents differs by race and is related to infant birth weight z-score

ENDOCRINOLOGY IN PREGNANCY: Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture

Contact Info

Product

Resources

About